Aerie Pharmaceuticals (AERI) : The total negative money flow of $12.83 million on Friday indicates selling on strength. The inflow of money on upticks was $2.1 million, compared to $14.93 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.14. The negative money flow of $13.13 million in block trades reveals that the informed traders sold the stock on every bit of price strength.The transaction value of block trade on downtick was $13.13 million. The price action in the Aerie Pharmaceuticals (AERI) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $18.14 with a gain of $0.23 , a change of 1.28% over the previous days close. The stock registered 3.72% for the week.
Aerie Pharmaceuticals (AERI) : The highest short term price target forecast on Aerie Pharmaceuticals (AERI) is $50 and the lowest target price is $40. A total of 5 equity analysts are currently covering the company. The average price of all the analysts is $45.4 with a standard deviation of $3.85.
Aerie Pharmaceuticals (NASDAQ:AERI): stock turned positive on Friday. Though the stock opened at $18.03, the bulls momentum made the stock top out at $18.39 level for the day. The stock recorded a low of $17.5 and closed the trading day at $18.14, in the green by 1.28%. The total traded volume for the day was 1,258,328. The stock had closed at $17.91 in the previous days trading.
In a related news, Cagle Gerald D., director of Aerie Pharmaceuticals Inc, had purchased 4,646 shares on February 4, 2015. The total value of the transaction was $84,743. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Companys primary product candidates, triple-action Rhopressa and quadruple-action Roclatan, are once-daily eye drops. The Companys product candidate, once-daily, quadruple-action Roclatan, is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET), which are both biochemical targets for lowering intraocular pressure (IOP). The Companys Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533, its second-generation ROCK/NET inhibitor.